Department of Medicinal Chemistry, Bayer Schering Pharma AG, Global Drug Discovery, 42096 Wuppertal, Germany.
J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.
Limitations of current steroidal mineralocorticoid receptor (MR) antagonists have stimulated the search for a new generation of molecules. We screened for novel nonsteroidal compounds and identified MR antagonists derived from the chemical class of dihydropyridines. Chemical optimization resulted in BR-4628, which displays high in vitro and in vivo MR potency as well as selectivity with respect to the other steroid hormone receptors and the L-type calcium channel. Biochemical studies demonstrated that BR-4628 forms complexes with MR that do not promote the recruitment of transcriptional co-regulators. Docking experiments, using the crystal structure of the MR ligand-binding domain in an agonist conformation, revealed that BR-4628 accommodates in the MR ligand-binding cavity differently in comparison with the classical steroidal MR antagonists. An alanine scanning mutagenesis approach, based on BR-4628 docking, allowed identifying its anchoring mode within the ligand-binding cavity. Altogether, we propose that BR-4628 is a bulky antagonist that inactivates MR through a passive mechanism. It represents the prototype of a new class of MR antagonists.
目前甾体类盐皮质激素受体(MR)拮抗剂的局限性促使人们寻找新一代分子。我们筛选了新型非甾体化合物,并从二氢吡啶类化合物的化学类别中鉴定出 MR 拮抗剂。通过化学优化得到了 BR-4628,它在体外和体内均表现出高 MR 活性和选择性,相对于其他甾体激素受体和 L 型钙通道。生化研究表明,BR-4628 与 MR 形成复合物,不会促进转录共调节剂的募集。使用激动剂构象的 MR 配体结合域晶体结构进行对接实验表明,与经典甾体 MR 拮抗剂相比,BR-4628 在 MR 配体结合腔内的容纳方式不同。基于 BR-4628 对接的丙氨酸扫描诱变方法允许确定其在配体结合腔内的锚定模式。总的来说,我们提出 BR-4628 是一种通过被动机制失活 MR 的大型拮抗剂。它代表了一类新型 MR 拮抗剂的原型。